Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split

Executive Summary

A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.

You may also be interested in...



Pfizer's Practical Predator: CEO Ian Read

The naturalized US citizen's M&A method means mixing money and medicines in a tax-efficient manner. Interactive timeline tracks major acquisitions and divestitures during Read's tenure.

Deal Watch: AstraZeneca/Almirall And Pfizer/Baxter Vaccines Deal Change Math On Future Pfizer/AstraZeneca Bid

Meda acquires family-owned Italian firm Rottapharm for $3.1 billion, expanding its European and emerging markets business. Boehringer Ingelheim and Zealand sign their second collaboration, this time around peptide candidates for cardio-metabolic disease.

Vaccines Chess Game Continues With Baxter Sale To Pfizer

Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel